Credit Suisse and Deutsche Bank will be the joint bookrunning managers
By Devika Patel
Knoxville, Tenn., Nov. 21 - Evogene Ltd. said it priced its $73.75 million initial public offering of stock with an $11.06 million greenshoe. The deal was announced Nov. 6.
The company will sell 5 million ordinary shares at $14.75 per share.
Monsanto Co. is expected to invest $12 million.
Credit Suisse Securities and Deutsche Bank Securities are the joint bookrunning managers.
Settlement is expected Nov. 26.
Proceeds will be used to develop and expand the company's ag-chemical operations and develop and commercialize its Evofuel activities.
The plant genomics company is based in Rehovot, Israel. It intends to list its stock on the New York Stock Exchange under the symbol "EVGN."
| Issuer: | Evogene Ltd.
|
| Issue: | Ordinary stock
|
| Amount: | $73.75 million
|
| Greenshoe: | $11,062,500
|
| Shares: | 5 million
|
| Price: | $14.75
|
| Warrants: | No
|
| Bookrunners: | Credit Suisse Securities and Deutsche Bank Securities
|
| Co-managers: | Oppenheimer & Co. and Piper Jaffray & Co.
|
| Investor: | Monsanto Co. (for $12 million)
|
| Announcement date: | Nov. 6
|
| Pricing date: | Nov. 21
|
| Settlement date: | Nov. 26
|
| Stock exchange: | NYSE: EVGN
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
